Chitosan microparticles for delivery of proteins to the retina

Acta Biomaterialia

Volumn 9, Issue 8, 2013, Pages 7855-7864

  Wassmer, Sarah ^a,b   Rafat, Mehrdad ^a,c   Fong, Wai Gin ^a   Baker, Adam N ^a   Tsilfidis, Catherine ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Biodegradation; Chitosan; Encapsulation; Microparticles; Retina

Indexed keywords

BIOCOMPATIBILITY; BODY FLUIDS; CHITOSAN; CYTOTOXICITY; OPHTHALMOLOGY; PROTEINS; VISION;

BOVINE SERUM ALBUMINS; CHITOSAN MICROPARTICLES; CYTOTOXIC EFFECTS; IN-VITRO; LOW CONCENTRATIONS; MICRO PARTICLES; RELEASE KINETICS; RETINA; RETINAL CELLS; TOPICAL APPLICATION;

BIODEGRADATION;

BOVINE SERUM ALBUMIN; CHITOSAN; CHITOSAN MICROPARTICLE; ENHANCED GREEN FLUORESCENT PROTEIN; NANOPARTICLE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; PROTEIN; MICROCAPSULE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CELL ENCAPSULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ELECTRORETINOGRAM; FUNDUS CAMERA; HISTOLOGY; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KINETICS; MOUSE; NONHUMAN; PHOTORECEPTOR; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; RETINA CELL; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; CELL CULTURE; CHEMISTRY; DIFFUSION; DRUG EFFECT; INTRAOCULAR DRUG ADMINISTRATION; LONG EVANS RAT; MATERIALS TESTING; METABOLIC CLEARANCE RATE; METABOLISM; MICROCAPSULE; RETINA; SYNTHESIS; ADMINISTRATION AND DOSAGE; DRUG EFFECTS;

BOVINAE;

ANIMALS; CAPSULES; CELLS, CULTURED; CHITOSAN; DIFFUSION; INJECTIONS, INTRAOCULAR; MATERIALS TESTING; METABOLIC CLEARANCE RATE; MICE; PROTEINS; RATS, LONG-EVANS; RETINA;

EID: 84891665626     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2013.04.025     Document Type: Article

References (35)

1. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008;358:2231-9.
2. Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, Boye SL, et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 2009;20:999-1004.
3. Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, Boye SL, et al. Vision 1 year after gene therapy for Leber's congenital amaurosis. N Engl J Med 2009;361:725-7.
4. Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L, et al. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008;19:979-90.
5. Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F, et al. Agedependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009;374:1597-605.
6. Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, Bennicelli JL, et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010;18:643-50.
7. Rafat M, Cleroux CA, Fong WG, Baker AN, Leonard BC, O'Connor MD, et al. PEG-PLA microparticles for encapsulation and delivery of Tat-EGFP to retinal cells. Biomaterials 2010;31:3414-21.
8. Wang XH, Li DP, Wang WJ, Feng QL, Cui FZ, Xu YX, et al. Crosslinked collagen/ chitosan matrix for artificial livers. Biomaterials 2003;24:3213-20.
9. Gingras M, Paradis I, Berthod F. Nerve regeneration in a collagen-chitosan tissue-engineered skin transplanted on nude mice. Biomaterials 2003;24:1653-61.
10. Kratz G, Arnander C, Swedenborg J, Back M, Falk C, Gouda I, et al. Heparin-chitosan complexes stimulate wound healing in human skin. Scand J Plast Reconstr Surg Hand Surg 1997;31:119-23.
11. Aiedeh K, Gianasi E, Orienti I, Zecchi V. Chitosan microcapsules as controlled release systems for insulin. J Microencapsul 1997;14:567-76.
12. Madihally SV, Matthew HW. Porous chitosan scaffolds for tissue engineering. Biomaterials 1999;20:1133-42.
13. Yagi K, Michibayashi N, Kurikawa N, Nakashima Y, Mizoguchi T, Harada A, et al. Effectiveness of fructose-modified chitosan as a scaffold for hepatocyte attachment. Biol Pharm Bull 1997;20:1290-4.
14. Illum L, Farraj NF, Davis SS. Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 1994;11:1186-9.
15. Lee M, Nah JW, Kwon Y, Koh JJ, Ko KS, Kim SW. Water-soluble and low molecular weight chitosan-based plasmid DNA delivery. Pharm Res 2001;18:427-31.
16. Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 1994;11:1358-61.
17. Thanou M, Verhoef JC, Junginger HE. Chitosan and its derivatives as intestinal absorption enhancers. Adv Drug Deliv Rev 2001;50(Suppl. 1):S91-101.
18. Guang Liu W, De Yao K. Chitosan and its derivatives - a promising non-viral vector for gene transfection. J Control Release 2002;83:1-11.
19. Basaran E, Yazan Y. Ocular application of chitosan. Expert Opin Drug Deliv 2012;9:701-12.
20. Klausner EA, Zhang Z, Chapman RL, Multack RF, Volin MV. Ultrapure chitosan oligomers as carriers for corneal gene transfer. Biomaterials 2010;31:1814-20.
21. Klausner EA, Zhang Z, Wong SP, Chapman RL, Volin MV, Harbottle RP. Corneal gene delivery: chitosan oligomer as a carrier of CpG rich, CpG free or S/MAR plasmid DNA. J Gene Med 2012;14:100-8.
22. Prow TW, Bhutto I, Kim SY, Grebe R, Merges C, McLeod DS, et al. Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium. Nanomedicine 2008;4:340-9.
23. Puras G, Zarate J, Aceves M, Murua A, Diaz AR, Aviles-Triguero M, et al. Low molecular weight oligochitosans for non-viral retinal gene therapy. Eur J Pharm Biopharm 2013;83:131-40.
24. Puras G, Zarate J, Diaz-Tahoces A, Aviles-Trigueros M, Fernandez E, Pedraz JL. Oligochitosan polyplexes as carriers for retinal gene delivery. Eur J Pharm Sci 2013;48:323-31.
25. Yang H, Wang R, Gu Q, Zhang X. Feasibility study of chitosan as intravitreous tamponade material. Graefes Arch Clin Exp Ophthalmol 2008;246:1097-105.
26. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci 1997;63:125-32.
27. de la Fuente M, Seijo B, Alonso MJ. Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy. Invest Ophthalmol Vis Sci 2008;49:2016-24.
28. Zadro-Lamoureux LA, Zacks DN, Baker AN, Zheng QD, Hauswirth WW, Tsilfidis C. XIAP effects on retinal detachment-induced photoreceptor apoptosis. Invest Ophthalmol Vis Sci 2009;50:1448-53.
29. Renwick J, Narang MA, Coupland SG, Xuan JY, Baker AN, Brousseau J, et al. XIAP-mediated neuroprotection in retinal ischemia. Gene Ther 2006;13:339-47.
30. Calija B, Cekic N, Savic S, Krajisnik D, Daniels R, Milic J. An investigation of formulation factors affecting feasibility of alginate-chitosan microparticles for oral delivery of naproxen. Arch Pharm Res 2011;34:919-29.
31. Hu YL, Qi W, Han F, Shao JZ, Gao JQ. Toxicity evaluation of biodegradable chitosan nanoparticles using a zebrafish embryo model. Int J Nanomed 2011;6:3351-9.
32. Prego C, Garcia M, Torres D, Alonso MJ. Transmucosal macromolecular drug delivery. J Control Release 2005;101:151-62.
33. Prego C, Torres D, Fernandez-Megia E, Novoa-Carballal R, Quinoa E, Alonso MJ. Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan PEGylation degree. J Control Release 2006;111:299-308.
34. Leonard KC, Petrin D, Coupland SG, Baker AN, Leonard BC, LaCasse EC, et al. XIAP protection of photoreceptors in animal models of retinitis pigmentosa. PLoS One 2007;2:e314.
35. Timmers AM, Zhang H, Squitieri A, Gonzalez-Pola C. Subretinal injections in rodent eyes: effects on electrophysiology and histology of rat retina. Mol Vis 2001;7:131-7.